TRB Chemedica International

TRB Chemedica International is a Swiss-based pharmaceutical and medical device company specializing in the research, development, and manufacturing of innovative treatments for rheumatology, ophthalmology, and neurology. Founded in 1980, the company is globally recognized for its expertise in hyaluronic acid-based therapies, producing market-leading brands such as OSTENIL for osteoarthritis and VISMED for dry eye syndrome. TRB Chemedica operates a vertically integrated business model, maintaining its own R&D centers and GMP-certified manufacturing facilities in Switzerland and Argentina. The company has a significant international footprint, with subsidiaries across Europe, Asia, and Latin America, and products distributed in over 70 countries. Their portfolio focuses on niche therapeutic areas where they provide high-quality, specialized solutions for chronic inflammatory and degenerative conditions.